Qurient acquires U.S. approval of Phase II clinical trial for MDR TB therapy Telacebec
Qurient(CEO Ki-Yeon Nam) announced a beginning of a Phase II clinical to globally develop a multi-drug resistant(MDR) tuberculosis(TB) therapy on the 17th of July.
Qurient said the company will start the Phase II clinical trial for its First-in-Class MDR TB therapy Telacebec based on the Phase I...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.